ClinicalTrials.gg
CompletedNCT00564629Updated Oct 19, 2016Results posted

Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males

A Phase 3 interventional study of Intravenous acetaminophen plus oral placebo and Oral acetaminophen plus IV placebo in Fever, sponsored by Mallinckrodt. Completed at 1 site in United States. Open to male participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-19.

Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing acetaminophen in Fever — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Fever.

Enrollment
14th of 31
105 · median 100
Started
2007
with 4 others
Phase 3
8 of 31
none open now
Registered
8th of 31
by date
Lead sponsor
5 of 31
Mallinckrodt

Among the 31 studies testing acetaminophen in Fever, this one is the 14th largest by enrollment, is one of 5 that started in 2007, is one of 8 in phase 3, and was the 8th registered.

Fever

438 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

1 of the 31 studies testing acetaminophen in Fever is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing acetaminophen in Fever, or all of them as a file.
02

Study summary

To assess the rapidity of onset of antipyretic effect and the efficacy and safety of a single dose of IV acetaminophen (IV APAP) versus oral (PO) acetaminophen in the treatment of fever induced by a standard dose of endotoxin

Read the detailed description

A Phase III, Randomized, Double-Blind, Double-Dummy, Single-Dose Study of the Efficacy and Safety of Intravenous Acetaminophen Versus Oral Acetaminophen for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

03

Conditions studied

  • Fever

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Screening) To be eligible for entry into the Study, Subjects must meet all of the following criteria at Screening:

  • Provide written prior to participation in the Study
  • Be a healthy male between the ages of 18 and 75 years of age, inclusive, at Randomization
  • Have a (BMI) ≥ 19 and ≤ 45 lbs/in2
  • Have the ability to read and understand the Study procedures and have the ability to communicate meaningfully with the Study Investigator and staff
  • Be free of physical, mental, or medical conditions which, in the opinion of the Investigator, may confound quantifying assessments for the Study
  • Be willing to abstain from smoking cigarettes or using nicotine products from the time of admission to Clinic until Study Completion

Inclusion Criteria (Pre-Randomization) To be eligible for Randomization, Subjects must meet each of the following criteria:

  • Be free of evidence of infection based upon clinical assessment and blood (Complete Blood Count- CBC) and urine testing
  • Have an average baseline oral temperature that is equal to or below 37 ºC (98.6 ºF) and does not vary more than 0.4 ºC (0.7 ºF) from lowest to highest on three assessments performed during a 30-minute period
  • Not develop a medically significant allergic or exaggerated systemic response to administration of a test dose of reference standard endotoxin
  • Develop a core temperature of at least 38.6 ºC (101.5 ºF) after IV reference standard endotoxin dosed per Study guidelines and have a fever response to endotoxin that is at or near the peak temperature by virtue of two consecutive temperature assessments 5 minutes apart that are within 0.2 ºC (0.4 ºF) of each other

Exclusion Criteria:

  • Has been treated with any medication having antipyretic effects (e.g., ,non-steroidal anti-inflammatory drug [NSAID], aspirin, or acetaminophen) within 2 days of clinic admission (aspirin at low dose for cardiac prophylaxis is allowed, but should not be taken on the day of the Study)
  • Has significant medical disease(s), laboratory abnormalities, or condition(s) that in the Investigator's judgment could compromise the Subject's welfare, ability to communicate with the Study staff, complete Study activities, or would otherwise contraindicate Study participation
  • Has known or to receiving endotoxin that in the Investigator's clinical judgment merits discontinuation from further Study participation
  • Has known hypersensitivity to acetaminophen, the inactive ingredients () of the intravenous (IV) or oral (PO) acetaminophen formulation or the Rescue Medications (ibuprofen, aspirin, and ketorolac)
  • Has known or suspected recent history of alcohol or drug abuse or dependence as defined by Diagnostic Statistical Manual of Mental Disorders, 4th Edition () criteria
  • Has a history of nasal polyps, angioedema, significant or actively treated bronchospastic disease, or any other significant medical condition that contraindicates participation in the Study or receiving endotoxin, Study Medication, or Rescue Medication
  • Has an active infection or other disease or condition that may cause abnormal alterations in body temperature
  • Has impaired liver function, e.g. (ALT) greater than or equal to 3 times the , greater than 3.0, active hepatic disease, or evidence of liver disease (e.g., cirrhosis or hepatitis)
  • Has participated in another clinical Study ( or marketed product) within 30 days of Screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    IV acetaminophen plus oral placebo.

    Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive 1 g of acetaminophen in 100 ml of intravenous solution and oral placebo.

    Drug: Intravenous acetaminophen plus oral placebo · Biological: Reference standard endotoxin (RSE)

  • Active comparator
    Oral acetaminophen plus IV placebo.

    Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive oral acetaminophen 1 g plus 100 ml of intravenous placebo solution.

    Drug: Oral acetaminophen plus IV placebo · Biological: Reference standard endotoxin (RSE)

Interventions

  • DrugIntravenous acetaminophen plus oral placebo

    Drug page: Acetaminophen

    Single dose of 1 gm IV acetaminophen

    Also known as: IV APAP

  • DrugOral acetaminophen plus IV placebo

    Drug page: Acetaminophen

    Single dose of 1 g PO APAP

    Also known as: IV APAP

  • BiologicalReference standard endotoxin (RSE)

    To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.

    Also known as: RSE

06

What researchers measure

Primary outcomes

  1. The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2)

    This outcome measures when the antipyretic effect begins by statistical analysis of WSTD2, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 2 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

    Time frame: 0-2 hours

Secondary outcomes

  1. Time to a Reduction in Temperature From T0 to T360 Minutes.

    This outcome measures how much time it took to observe a decrease in subjects' core body temperature by 0.8 ºC, 1.0 ºC, and 1.5 ºC from the temperature at T0 and from the temperature at the peak after T0 through T360 (6 hours). The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

    Time frame: 6 hours

  2. Maximum Temperature Reduction Observed From T0 to T360 Minutes

    This outcome measures the maximum core temperature reduction observed from T0 to T360 minutes. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

    Time frame: T0-T360 minutes

  3. Subject's Global Evaluation of Study Medication at T360 Minutes

    This outcome measures how satisfied the subject was with the study treatment. The subject was asked to answer "Overall, how would you rate study treatments?" at T360 minutes using a 4-point categorical scale (0=poor, 1=fair, 2=good, 3=excellent).

    Time frame: T360 minutes

  4. The Percentage of Subjects With Temperature < 38 ºC and < 38.5 ºC at Any Timepoint During the Time From T0 to T360 Minutes

    This outcome measures what percentage of total subjects had a temperature \< 38 ºC and \< 38.5 ºC at any timepoint during the time from T0 to T360 minutes.

    Time frame: T0 to T360 minutes

  5. WSTD3

    This outcome measure is a statistical analysis of WSTD3, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 3 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

    Time frame: 0-3 hours

  6. WSTD4

    This outcome measure is a statistical analysis of WSTD4, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 4 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

    Time frame: 0-4 hours

  7. WSTD5

    This outcome measure is a statistical analysis of WSTD5, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 5 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

    Time frame: 0-5 hours

  8. WSTD6

    This outcome measure is a statistical analysis of WSTD6, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 6 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

    Time frame: 0-6 hours

07

Results

Posted Sep 21, 2010
Limitations and caveats
Protocol and statistical analysis plan were amended to clarify endpoints prior to database lock and analysis.

Participant flow

Healthy Adult males at one site in the United States

Participant flow — Overall Study
MilestoneOral Acetaminophen (PO APAP) 1 gIntravenous Acetaminophen (IV APAP) 1 g / 100 ml Solution
Started5154
Completed3645
Not completed159
Withdrew: Vomited within 2 hours of receiving drug159

Outcome measures

PrimaryThe Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2)

This outcome measures when the antipyretic effect begins by statistical analysis of WSTD2, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 2 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

Time frame:
0-2 hours
Reported as:
Mean · Degrees Celsius
The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2)
Degrees CelsiusIV APAP 1 g / 100 ml SolutionPO APAP 1 g
The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2)0.3 ± 0.410.6 ± 0.55
SecondaryTime to a Reduction in Temperature From T0 to T360 Minutes.

This outcome measures how much time it took to observe a decrease in subjects' core body temperature by 0.8 ºC, 1.0 ºC, and 1.5 ºC from the temperature at T0 and from the temperature at the peak after T0 through T360 (6 hours). The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

Time frame:
6 hours
Reported as:
Mean · Hours
Time to a Reduction in Temperature From T0 to T360 Minutes.
HoursIV APAP 1 g / 100 ml SolutionPO APAP 1 g
reduction in temperature of 0.8 ºC from T0 temp4.8 ± 0.964.7 ± 1.41
reduction in temp of 0.8 ºC from the peak T0-T3603.5 ± 1.232.4 ± 1.16
reduction in temperature of 1.0 ºC from T0 temp5.1 ± 0.855.0 ± 1.24
reduction in temp of 1.0 ºC from the peak T0-T3603.8 ± 0.872.9 ± 1.16
reduction in temperature of 1.5 ºC from T0 temp5.7 ± 0.455.6 ± 0.64
reduction in temp of 1.5 ºC from the peak T0-T3605.1 ± 0.174.2 ± 1.19
SecondaryMaximum Temperature Reduction Observed From T0 to T360 Minutes

This outcome measures the maximum core temperature reduction observed from T0 to T360 minutes. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

Time frame:
T0-T360 minutes
Reported as:
Mean · Degrees Celsius
Maximum Temperature Reduction Observed From T0 to T360 Minutes
Degrees CelsiusIV APAP 1 g / 100 ml SolutionPO APAP 1 g
Maximum Temperature Reduction Observed From T0 to T360 Minutes-0.8 ± 0.46-1.1 ± 0.42
SecondarySubject's Global Evaluation of Study Medication at T360 Minutes

This outcome measures how satisfied the subject was with the study treatment. The subject was asked to answer "Overall, how would you rate study treatments?" at T360 minutes using a 4-point categorical scale (0=poor, 1=fair, 2=good, 3=excellent).

Time frame:
T360 minutes
Reported as:
Number · participants
Subject's Global Evaluation of Study Medication at T360 Minutes
participantsIV APAP 1 g / 100 ml SolutionPO APAP 1 g
Poor (0)02
Fair (1)72
Good (2)1811
Excellent (3)2021
SecondaryThe Percentage of Subjects With Temperature < 38 ºC and < 38.5 ºC at Any Timepoint During the Time From T0 to T360 Minutes

This outcome measures what percentage of total subjects had a temperature \< 38 ºC and \< 38.5 ºC at any timepoint during the time from T0 to T360 minutes.

Time frame:
T0 to T360 minutes
Reported as:
Number · percentage of participants
The Percentage of Subjects With Temperature < 38 ºC and < 38.5 ºC at Any Timepoint During the Time From T0 to T360 Minutes
percentage of participantsIV APAP 1 g / 100 ml SolutionPO APAP 1 g
temperature < 38 ºC4067
temperature < 38.5 ºC8492
SecondaryWSTD3

This outcome measure is a statistical analysis of WSTD3, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 3 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

Time frame:
0-3 hours
Reported as:
Mean · degrees Celsius
WSTD3
degrees CelsiusIV APAP 1 g / 100 ml SolutionPO APAP 1 g
WSTD30.2 ± 0.730.5 ± 0.85
SecondaryWSTD4

This outcome measure is a statistical analysis of WSTD4, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 4 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

Time frame:
0-4 hours
Reported as:
Mean · degrees Celsius
WSTD4
degrees CelsiusIV APAP 1 g / 100 ml SolutionPO APAP 1 g
WSTD4-0.20 ± 1.06-0.02 ± 1.12
SecondaryWSTD5

This outcome measure is a statistical analysis of WSTD5, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 5 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

Time frame:
0-5 hours
Reported as:
Mean · degrees Celsius
WSTD5
degrees CelsiusIV APAP 1 g / 100 ml SolutionPO APAP 1 g
WSTD5-0.7 ± 1.43-0.7 ± 1.41
SecondaryWSTD6

This outcome measure is a statistical analysis of WSTD6, which is the weighted sum of temperature differences from the subject's core temperature at each assessment time point through the first 6 hours compared with the subject's core temperature at T0, weighted by the time elapsed between each 2 consecutive time points. The subject's core temperature was measured using an ingestible temperature monitoring capsule and associated data recorder.

Time frame:
0-6 hours
Reported as:
Mean · degrees Celsius
WSTD6
degrees CelsiusIV APAP 1 g / 100 ml SolutionPO APAP 1 g
WSTD6-1.4 ± 1.88-1.7 ± 1.70

Adverse events

Collected over Treatment Emergent Adverse Events(TEAEs)were reported from T0 (on or after the start of study medication) to 6 hours after study medication was administered to the subject.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Acetaminophen (PO APAP) 1 g—0/51 (0%)17/51 (33.3%)
Intravenous Acetaminophen (IV APAP) 1 g / 100 ml Solution—0/54 (0%)13/54 (24.1%)
Most frequent other events
Most frequent other events
EventOral Acetaminophen (PO APAP) 1 gIntravenous Acetaminophen (IV APAP) 1 g / 100 ml Solution
VomitingGastrointestinal disorders13/516/54
DiarrhoeaGastrointestinal disorders5/514/54
HeadacheNervous system disorders4/515/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PO APAP 1 gIV APAP 1 g / 100 ml SolutionTotal
<=18 years000
Between 18 and 65 years5154105
>=65 years000
Age, Continuous
Age, Continuous(years)PO APAP 1 gIV APAP 1 g / 100 ml SolutionTotal
Mean32.1 ± 9.0733.8 ± 11.633 ± 10.52
Sex: Female, Male
Sex: Female, Male(Participants)PO APAP 1 gIV APAP 1 g / 100 ml SolutionTotal
Female000
Male5154105
Region of Enrollment
Region of Enrollment(participants)PO APAP 1 gIV APAP 1 g / 100 ml SolutionTotal
United States5154105
08

Study locations

1 site
  • New Orleans Center for Clinical Research-Knoxville
    Knoxville, Tennessee 37920, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 2 years 11 months after primary completion. A results delay was requested in Apr 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2007
First posted
Nov 28, 2007
Start
Aug 2007
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results delay requested
Apr 3, 2009
Results first posted
Sep 21, 2010
Last update
Oct 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00564629
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Nov 28, 2007
Start date
Aug 2007
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Sep 21, 2010
Last update
Oct 19, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion